Overview

Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

OBJECTIVES: I. Determine the safety of immune ablation with high-dose cyclophosphamide and anti-thymocyte globulin followed by peripheral blood stem cell support in patients with systemic lupus erythematosus.

Phase:

Phase 1

Details

Lead Sponsor:

Northwestern Memorial Hospital

Treatments:

Antilymphocyte Serum
Cyclophosphamide